Medical Prognosis Institute Selects Insightful Corporation for Predictive Analytics and Reporting
10 Aprile 2008 - 10:00PM
Business Wire
Insightful Corporation (NASDAQ:IFUL), a leading provider of
predictive analytics and reporting solutions, announced today that
Medical Prognosis Institute (http://medical-prognosis.com), a
provider of leading-edge technology based on DNA microarrays, has
selected S-PLUS� 8 Enterprise Server, Insightful�s software
platform for statistical data analysis and predictive analytics.
Medical Prognosis Institute will utilize S-PLUS 8 Enterprise Server
for deploying analytic models originally prototyped in R, the free
open-source dialect of Insightful�s S language. �We selected S-PLUS
after a thorough review of applicable technologies, including R
which we have been using,� said Dr. Steen Knudsen, chief scientific
officer of Medical Prognosis Institute. �Insightful�s S-PLUS server
and the S+ArrayAnalyzer� solution provide a robust, extensible
technology framework and are readily validated within our
environment. In addition, I was very pleased that in less than 20
hours I was able to easily port our R code into S-PLUS for
deployment with the S-PLUS server.� �In today�s highly competitive
drug discovery and development environment, it�s crucial that life
science companies arm themselves with the tools they need to both
meet the requirements of a validated environment and provide
significant gains in productivity and efficiency,� said Jeff
Coombs, president and CEO of Insightful. �We are pleased that
Medical Prognosis Institute has recognized what an asset S-PLUS can
be and decided to standardize on it.� Insightful Life Sciences
Solutions Provide the Knowledge to Act� Insightful provides life
sciences organizations with the knowledge they need to drive
faster, better decisions with specialized analytics, graphics and
reporting formats. Insightful offers predictive analytic software
and service solutions in clinical graphics, PK/PD reporting,
clinical data review, innovative trial design, and safety data
mining. These solutions are designed to act in concert with
existing data management and workflow systems within validated
environments to speed the analysis and reporting processes, to
increase the likelihood of discerning safety and efficacy signals
earlier in the development lifecycle. ABOUT MEDICAL PROGNOSIS
INSTITUTE Headquartered in H�rsholm, Denmark, Medical Prognosis
Institute�s (MPI) mission is to improve cancer treatment with
leading-edge technology based on DNA microarrays. MPI uses
proprietary individualized genomic profiling of tumor tissue for
prognostication of individual patients and for determining which
cancer patients will benefit from which specific chemotherapy
and/or radiation therapy. MPI is currently conducting clinical
trials to validate its claims that its products and services will
give cancer patients and oncologists necessary insight to help make
better treatment decisions. In addition, MPI recently began
providing its fast turn-around, high-quality DNA microarray
services on a fee-for-service basis to the academic and
biopharmaceutical industry in the discovery phase. For more
information, visit www.medical-prognosis.com, email
info@medical-prognosis.com or call +45 40862156. ABOUT INSIGHTFUL
CORPORATION Insightful Corporation (NASDAQ:IFUL) is a provider of
predictive analytics and reporting solutions. Insightful products
S-PLUS�, Insightful Miner� and S-PLUS� Enterprise Server allow
companies to perform sophisticated statistical data analysis and
data mining and create high-quality graphics and reports.
Insightful has been delivering industry-leading, high-ROI solutions
to thousands of companies in financial services, life sciences,
telecommunications, and manufacturing, plus government and research
institutions, for 20 years. Headquartered in Seattle, Insightful
has offices in New York, North Carolina, the United Kingdom,
Switzerland, France and Hong Kong, with distributors around the
world. For more information, visit www.insightful.com, email
info@insightful.com or call 1-800-569-0123. Note to Investors �
Forward Looking Statements This press release contains
forward-looking statements, including statements about the
potential performance and advantages of our life sciences solutions
and their potential value to MPI and other customers.
Forward-looking statements are based on the judgment and opinions
of management at the time the statements are made. Inaccurate
assumptions and known and unknown risks and uncertainties can
affect the accuracy of forward-looking statements. Actual results
could differ materially from those expressed or implied by the
forward-looking statements for a number of reasons, including,
without limitation, the risk that our products do not perform as
designed and expected. More detailed information regarding these
and other factors that could affect actual results is set forth in
our filings with the Securities and Exchange Commission, including
our most recent report on Form 10-KSB. You should not unduly rely
on these forward-looking statements, which apply only as of the
date of this release. We undertake no obligation to update publicly
any forward-looking statements to reflect new information, events
or circumstances after the date of this release or to reflect the
occurrence of anticipated events.
Grafico Azioni Insightful (NASDAQ:IFUL)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Insightful (NASDAQ:IFUL)
Storico
Da Set 2023 a Set 2024